In the United States, clinical testing is monitored by the federal and state governments, held to standards to ensure the safety and efficacy of these tests, as well as maintaining privacy for patients receiving a test. In order for the ABCTL to lawfully operate in the state of Arizona, it had to meet various legal criteria. These major legal considerations, in no particular order, are: Clinical Laboratory Improvement Amendments compliance; FDA Emergency Use Authorization (EUA); Health Insurance Portability and Accountability Act compliance; state licensure; patient, state, and federal result reporting; and liability. <br/>In this paper, the EUA pathway will be examined and contextualized in relation to the ABCTL. This will include an examination of the FDA regulations and policies that affect the laboratory during its operations, as well as a look at the different authorization pathways for diagnostic tests present during the COVID-19 pandemic.
Details
- The Making of a COVID Testing Laboratory: The FDA Emergency Use Authorization Pathway’s Impact on the ABCTL
- Jenkins, Landon James (Co-author)
- Espinoza, Hale Anna (Co-author)
- Filipek, Marina (Co-author)
- Ross, Nathaniel (Co-author)
- Salvatierra, Madeline (Co-author)
- Compton, Carolyn (Thesis director)
- Rigoni, Adam (Committee member)
- Stanford, Michael (Committee member)
- School of Life Sciences (Contributor)
- School of Politics and Global Studies (Contributor)
- Barrett, The Honors College (Contributor)